Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.
Intern Med J. 2012 Dec;42(12):1351-4. doi: 10.1111/imj.12007.
A patient with pulmonary arterial hypertension secondary to systemic sclerosis was successfully treated with sitaxentan prior to its worldwide withdrawal (because of hepatotoxicity concerns), but then ironically experienced acute hepatic dysfunction during substitute bosentan therapy, and was eventually stabilised on a phosphodiesterase-5 inhibitor.
一位患有系统性硬化症相关肺动脉高压的患者，在西他生坦（由于肝毒性问题）在全球撤市之前，成功接受了该药治疗，但随后在替代用波生坦治疗时却出现了急性肝功能障碍，最终在使用磷酸二酯酶-5 抑制剂后病情稳定。
